G1 Therapeutics (NASDAQ:GTHX) insider Rajesh Malik sold 3,776 shares of the firm’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $38.18, for a total value of $144,167.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Rajesh Malik also recently made the following trade(s):
- On Thursday, February 15th, Rajesh Malik sold 3,776 shares of G1 Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $75,520.00.
- On Tuesday, January 16th, Rajesh Malik sold 3,776 shares of G1 Therapeutics stock. The shares were sold at an average price of $22.96, for a total value of $86,696.96.
Shares of NASDAQ:GTHX opened at $35.37 on Friday. G1 Therapeutics has a 12 month low of $12.04 and a 12 month high of $42.78. The stock has a market cap of $1,164.88 and a PE ratio of -9.91.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). sell-side analysts predict that G1 Therapeutics will post -2.47 EPS for the current year.
GTHX has been the topic of several recent analyst reports. BTIG Research assumed coverage on shares of G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 target price on the stock. BidaskClub raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. JPMorgan Chase lifted their price objective on shares of G1 Therapeutics to $30.00 in a research note on Monday, February 5th. Zacks Investment Research lowered shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Finally, Cowen restated a “buy” rating on shares of G1 Therapeutics in a research report on Monday, March 5th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $38.20.
Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new position in G1 Therapeutics in the third quarter worth approximately $568,000. Franklin Resources Inc. raised its position in shares of G1 Therapeutics by 10.1% during the 4th quarter. Franklin Resources Inc. now owns 1,535,616 shares of the company’s stock valued at $30,467,000 after purchasing an additional 141,000 shares during the period. Swiss National Bank bought a new stake in shares of G1 Therapeutics during the 4th quarter valued at $286,000. Virtus Fund Advisers LLC bought a new stake in shares of G1 Therapeutics during the 4th quarter valued at $350,000. Finally, Ellington Management Group LLC bought a new stake in shares of G1 Therapeutics during the 4th quarter valued at $294,000. Hedge funds and other institutional investors own 42.78% of the company’s stock.
TRADEMARK VIOLATION WARNING: “G1 Therapeutics (NASDAQ:GTHX) Insider Sells $144,167.68 in Stock” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/rajesh-malik-sells-3776-shares-of-g1-therapeutics-inc-gthx-stock-2.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.